NCT02667288View on ClinicalTrials.gov

An Open-Label Safety Study of A-101 Solution

PHASE3CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Seborrheic Keratosis
Interventions
DRUG

A-101 Solution

Trial Locations (1)

19355

Aclaris Therapeutics, Inc., Malvern

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY